| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |